健之佳医药连锁集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：605266 证券简称：健之佳 公告编号：2025-033 | 1、出席会议的股东和代理人人数 | 153 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 82,286,230 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 53.2449 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次临时股东会由公司董事会召集，公司董事长蓝波先生主持，本次股东会 的召集、召开及表决方式符合《中华人民共和国公司法》等法律、法规及规范性 文件及《公司章程》的有关规定。 (一) 股东大会召开的时间：2025 年 5 月 21 日 (二) 股东大会召开的地点：云南省昆明市盘龙区联盟街道旗营街 10 号健之佳 总部 14 楼会议室 (三) ...

中国经济网北京5月19日讯健之佳（605266）(605266.SH)2024年年度报告显示，2024年，公司实现营业收入92.83亿元，同比增长 2.23%；归属于上市公司股东的净利润1.28亿元，同比下降69.08%；归属于上市公司股东的扣除非经常性损益的净利润1.24亿 元，同比下降68.89%；经营活动产生的现金流量净额为5.09亿元，同比下降50.32%。 健之佳发行募集资金总额为96,579.25万元，募集资金净额为87,450.16万元。健之佳2020年10月27日发布的招股说明书显示，健之 佳拟募集资金87,450.16万元，分别用于新开门店建设项目、医药连锁信息服务项目、全渠道多业态营销平台建设项目。 健之佳发行费用总额(不含税)为9,129.09万元，承销费用为6743.44万元，保荐费用为400万元。 健之佳2022年4月22日发布的非公开发行股票发行情况报告书显示，2022年4月13日，主承销商红塔证券已将扣除保荐和承销费后 的上述认购款划转至健之佳开立的募集资金专用账户。信永中和会计师事务所(特殊普通合伙)出具了XYZH/2022KMAA20033号 《验资报告》，确认发行人募集资金 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-032 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次被担保方云南健之佳连锁健康药房有限公司（以下简称"连锁药房"）、 广西健之佳勤康医药销售有限公司（以下简称"广西勤康"）、辽宁健之佳医药 有限公司（以下简称"辽宁健之佳医药"）为健之佳医药连锁集团股份有限公司 （以下简称"公司"）100%持股的全资子公司。 本次公司为上述 3 家全资子公司担保金额合计 12,000 万元，截至本公告 披露日，公司为连锁药房已实际提供的担保余额为 55,843.07 万元；为广西勤康 已实际提供的担保余额为 7,899.96 万元；为辽宁健之佳医药已实际提供的担保 余额为 980 万元。 截至公告披露日，公司对外担保均系为全资子公司提供的担保，不涉及 集团外担保，公司无逾期对外担保。 风险提示：截至本公告披露日，被担保方辽宁健之佳医药最近一期经审 计的资产负责率超过 70%；公司为全资子公司的担保 ...

健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司 JZJ Chain Drugstore Corporation 2024 年年度股东会 会议资料 股票代码：605266 2024 年年度股东会会议资料目录 | 会议须知 | | 3 | | --- | --- | --- | | 会议议程 | | 5 | | 2024 年度董事会工作报告 | 7 | | | 2024 年度监事会工作报告 | 12 | | | 2024 | 年度独立董事述职报告 15 | | | 2024 年度财务决算报告 | 17 | | | 2025 年度财务预算方案 | 25 | | | 2024 年度利润分配方案 | 27 | | | 关于公司《2024 | 年年度报告》及摘要的议案 29 | | | 关于续聘公司 | 2025 年度审计机构、内控审计机构的议案 | 30 | | | 关于公司及子公司向金融机构申请综合授信额度及为综合授信额度提供担保的 | | | 议案 | | 33 | | 关于公司 2025 | 年度日常关联交易预计的议案 | 42 | 2 健之佳医药连锁集团股份有限公司 股票简称：健之佳 中国 昆明 ...

关于参加云南辖区上市公司 2024 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，健之佳医药连锁集团股份有限公司（以 下简称"公司"）将参加由云南证监局指导，云南省上市公司协会与深圳市全景 网络有限公司联合举办的"2024 年度云南辖区上市公司投资者网上集体接待日"， 现将相关事项公告如下： 证券代码：605266 证券简称：健之佳 公告编号：2025-031 健之佳医药连锁集团股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2025 年 5 月 16 日（周五）16:00-17:00。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告！ 健之佳医药连锁集团股份有限公司董事会 2025 年 5 月 ...

近日，公司完成了减少注册资本的工商变更登记及修订《公司章程》的工商备案手续，并取得云南省市 场监督管理局换发的《营业执照》。 证券代码：605266 证券简称：健之佳 公告编号：2025-030 健之佳医药连锁集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据健之佳医药连锁集团股份有限公司（以下简称"公司"）2024年第二次临时股东会审议通过的《关于 终止实施2024年限制性股票激励计划暨回购注销限制性股票的议案》、《关于修订〈公司章程〉的议 案》，公司终止实施2024年限制性股票激励计划，回购并注销对261名激励对象已授予但尚未解除限售 的2,117,880股限制性股票，需变更注册资本、修订公司章程、办理工商变更登记。 本次回购、注销手续于2025年4月17日完成，注销后公司总股本由156,660,808股减少至154,542,928股。 具体内容详见于2025年4月19日在上海证券交易所网站（www.sse.com.cn）披露的《关于限制性股票回 购注销完成的公 ...

Core Insights - The chain pharmacy industry in 2024 is experiencing a significant slowdown, transitioning from a rapid expansion phase to one of reduced growth and declining profitability [2][3] - Six major private chain pharmacies reported revenue growth of less than 10%, with the highest being 8.01%, a stark contrast to previous years where many exceeded 20% [2] - Only Yifeng Pharmacy managed to achieve net profit growth, while the other five companies faced varying degrees of decline [2][5] Revenue and Profitability - Yifeng Pharmacy reported a revenue of 24.062 billion yuan with a net profit growth of 8.26%, becoming the only company to grow in a challenging environment [5] - Dazhenlin achieved the highest revenue of 26.497 billion yuan but saw a net profit decline of over 20% [5] - Laobaixing maintained a sales figure of 22.357 billion yuan, but its profits nearly halved [5] - Regional players like Shuyupingmin reported a loss of nearly 200 million yuan, while Jianzhijia's profits plummeted by about 70% [5] Store Expansion and Closure - Despite the overall industry challenges, the number of stores for major chain pharmacies continued to grow, with Dazhenlin adding 2,479 stores, Yifeng adding 1,434, and Laobaixing adding 1,703 [7] - The total number of closed pharmacies reached 25,114 in the first three quarters of 2024, with a growing trend in closures [5][6] Industry Challenges - The industry faces significant pressures from tightened healthcare policies, increased online competition, and changing consumer spending habits [3][8] - The competitive landscape has intensified, leading to price wars and promotional battles that compress profit margins [8] - Regulatory changes, such as stricter healthcare cost controls and increased compliance requirements, have further strained profitability [8][10] Strategic Responses - Companies are focusing on digital transformation and optimizing business structures to enhance efficiency and customer service [12] - Diversification into health products, beauty items, and health management services is becoming a strategic priority [12] - The integration of online and offline sales and services is seen as essential for future success, although it requires significant investment [12]

证券代码：605266 证券简称：健之佳 公告编号：2025-030 健之佳医药连锁集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据健之佳医药连锁集团股份有限公司（以下简称"公司"）2024年第二次 临时股东会审议通过的《关于终止实施2024年限制性股票激励计划暨回购注销限 制性股票的议案》、《关于修订<公司章程>的议案》，公司终止实施2024年限制性 股票激励计划，回购并注销对261名激励对象已授予但尚未解除限售的2,117,880 股限制性股票，需变更注册资本、修订公司章程、办理工商变更登记。 本次回购、注销手续于2025年4月17日完成，注销后公司总股本由 156,660,808股减少至154,542,928股。具体内容详见于2025年4月19日在上海证 券交易所网站（www.sse.com.cn）披露的《关于限制性股票回购注销完成的公告》 （公告编号：2024-015）。 近日，公司完成了减少注册资本的工商变更登记及修订《公司章程》的工商 备案手续，并取得 ...

Core Viewpoint - The retail pharmaceutical industry is undergoing significant adjustments due to deepening medical reform policies, increased competition, and the impact of e-commerce, leading to a decline in customer traffic and a challenging environment for store openings and closures [1][2]. Group 1: Industry Performance - The performance of listed chain pharmacies in 2024 shows a polarization, with Yifeng Pharmacy achieving revenue and net profit growth, while Lao Bai Xing experienced declines in both metrics [1][3]. - Shuyu Pingmin reported a substantial net profit decline of 241.90%, marking its first loss after years of profitability, while Yixin Tang's net profit fell to a ten-year low of 1.14 billion yuan, down 79.23% [1][3]. - The overall number of retail pharmacies is expected to decrease, with an estimated 39,000 closures in 2024, resulting in a closure rate of 5.7%, up from 3.8% in 2023 [4]. Group 2: Store Expansion and Strategy - Dacaren's expansion rate has slowed, with a net increase of 2,479 stores in 2024 compared to 4,029 in 2023, while other companies like Yifeng Pharmacy and Lao Bai Xing also reported slower store growth [1][4]. - Many companies are adjusting their store opening strategies, with Jianzhijia reducing its annual expansion plan to around 400 stores [4]. Group 3: Transformation and Innovation - Pharmaceutical retail enterprises are accelerating their transformation, with leading companies adopting the "pharmacy + clinic" model to create community health ecosystems [2][5]. - Companies are focusing on digital transformation and exploring synergies between e-commerce and physical stores to adapt to the changing market landscape [2][5]. Group 4: Financial Performance and Challenges - Shuyu Pingmin's revenue reached 9.57 billion yuan in 2024, a 4.13% increase, but its net profit turned negative due to various operational challenges [3]. - The decline in net profit for many companies is attributed to increased operational costs and the impact of new store openings, which, while contributing to revenue, also lead to higher expenses during their cultivation period [3][5]. Group 5: Market Trends and Consumer Behavior - The retail pharmacy industry is witnessing a shift towards diversified product offerings and a focus on patient-centered health services, moving away from reliance solely on pharmaceutical sales [5][6]. - The proportion of income from medical insurance settlements is decreasing for many companies, indicating a shift towards non-insurance revenue streams [8]. Group 6: O2O and Membership Growth - The O2O (Online to Offline) retail model is becoming a key growth driver, with significant increases in sales through this channel expected in 2024 [8][9]. - Membership numbers are growing across various companies, with Yifeng Pharmacy reporting a membership increase of 19.50% and a membership sales ratio of 82.03% [11].

Financial Performance - The company reported a net profit of RMB 317,645,097.68 for 2024, with a proposed cash dividend of RMB 11.00 per 10 shares, totaling RMB 162,973,874.80[6]. - The company's operating revenue for 2024 reached ¥9.28 billion, a 2.23% increase from ¥9.08 billion in 2023[21]. - Net profit attributable to shareholders decreased by 69.08% to ¥128.13 million in 2024 from ¥414.41 million in 2023[21]. - Basic earnings per share dropped to ¥0.83 in 2024, down 69.14% from ¥2.69 in 2023[22]. - The weighted average return on equity fell to 4.53% in 2024, a decrease of 10.69 percentage points from 15.22% in 2023[22]. - Operating cash flow net amount decreased by 50.32% to ¥508.98 million in 2024 from ¥1.02 billion in 2023[21]. - The total assets increased by 6.78% to ¥10.62 billion at the end of 2024 from ¥9.95 billion at the end of 2023[21]. - The company reported a significant increase in tax and additional fees by 48.97% to ¥53,388,258.15, driven by internal tax adjustments and compliance measures[84]. - The company's total revenue for the period reached approximately ¥9.28 billion, with a gross profit margin of 35.80%, reflecting a year-on-year increase of 2.23% in revenue and a decrease of 0.08% in gross profit margin[88]. - The company reported a total operating cost of 5.959 billion yuan, an increase of 2.35% compared to the previous year[94]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[10]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[10]. - The company has not faced any violations in decision-making procedures regarding external guarantees[10]. - The company has outlined potential risks in its management discussion and analysis section, which investors should review[10]. - The company is aware of industry policy risks and is actively improving internal compliance management to adapt to regulatory changes[141]. Strategic Developments - The company plans to slow down store expansion and control costs to adapt to policy changes and industry competition[28]. - The company aims to shift from merely meeting customer needs to stimulating demand through professional pharmaceutical services and health management[38]. - The company plans to leverage its store network to deepen omnichannel services and capture market share in both existing and new growth areas[38]. - The company is adjusting its short-term strategies to improve existing store performance and operational efficiency, while slowing down new store expansions[45]. - The company is committed to high-quality innovation and aims to strengthen operational efficiency and product competitiveness through strategic partnerships with pharmaceutical manufacturers[139]. Market Trends - The overall growth of the pharmaceutical health industry is slowing, with healthcare spending experiencing its first unusually low growth in years[38]. - The total scale of the health service industry in China is projected to expand from 9 trillion yuan in 2022 to 16 trillion yuan by 2030, indicating significant growth potential[40]. - The health industry is projected to grow from CNY 3.8 trillion in 2015 to CNY 16 trillion by 2030, driven by aging population and chronic disease trends[127]. - The retail pharmacy sector is expected to enhance professional pharmaceutical service capabilities to meet regulatory requirements and improve customer health safety[131]. Operational Efficiency - The company is investing in refined operational management, efficient logistics systems, and continuous optimization of information systems to ensure performance improvement[47]. - The company has implemented a comprehensive information system based on SAP/ERP, enhancing procurement, warehousing, and sales management[59]. - The logistics system has achieved high service levels with efficient sorting, delivery accuracy, and low cost rates, supporting rapid store expansion[58]. - The company is enhancing its digital operations and exploring the application of AI models to improve supply chain efficiency and operational management[149]. Shareholder Engagement - The company held 3 annual general meetings and 2 temporary general meetings during the reporting period, ensuring equal treatment of all shareholders and protecting the rights of minority shareholders[158]. - The company has implemented measures to protect the interests of all shareholders, particularly minority shareholders, during decision-making processes[158]. - The total equity increased to 18,468,648, with a capital reserve conversion of 3,862,405[160]. - The company plans to implement a stock incentive plan for 2024, including a draft for the employee stock ownership plan[168]. Community Engagement - The company conducted 53 "Health Home Community Activities" and 2,297 health promotion events across 53 regions, enhancing brand trust and member development[56]. - The company has established a stable and high-quality membership system with over 26 million effective members, with member consumption accounting for nearly 70%[71]. - The company has established 49 training bases to enhance the management and professional skills of its workforce[78]. Future Outlook - Future guidance indicates a projected revenue growth of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[161]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for this purpose[165]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs by the end of the fiscal year[165].